A Pharmacist-Physician Antibiotic Support Team

P and T

Volumn 29, Issue 1, 2004, Pages 33-40

  Pasquale, Timothy R ^a   Komorny, Kenneth M ^a   Letting Mangira, Dorcas ^a   Peshek, Stephanie ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE MANAGEMENT; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MALE; PATIENT CARE; PHARMACIST; PHYSICIAN; REVIEW; TEAMWORK;

EID: 1642576955     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: A population perspective. Emerg Infect Dis 2002;8(4):347-354. Available at: www.cdc.gov/ncidod/eid/vol8no4/01-0312.htm.
2. Belongia EA, Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ 1998;317:668-671.
3. John JF, Fishman NO. Programmatic role of infectious disease physicians in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-485.
4. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289-295.
5. Shlaes DM, Gerding DN, John JF Jr, et al., for the Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clin Infect Dis 1997;25:584-599.
6. Weinstein RA. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. Emerg Infect Dis 2001 7(2):188-192. Available at: www.cdc.gov/ncidod/eid/vol7no2/weinstein.htm.
7. Dickerson LM, Mainous AG III, Carek PJ. The pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy 2000;20(6):711-723.
8. Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999;19(12):1369-1377.
9. Dranitsaris G, Spizzirri D, Pitre M, McGeer A. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. Int J Tech Assess Health Care 2001;17(2):171-180.
10. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-755.
11. Fine MJ, Auble TE, Yealy DM, Hanusa BH. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
12. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001;161:848-850.
13. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge. Arch Intern Med 1999;159:2449-2454.
14. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
15. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intens Care Med 1996;22(5):387-394.
16. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-2572.
17. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451-457.
18. Malone DC, Shaban HM. Adherence to ATS Guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001;35:1180-1185.
19. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia in-patients in 10 western states: 1993, 1995, and 1997. Chest 2001;119:1420-1426.
20. Palmer CS, Zhan C, Elizhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000;22 (2):250-264.
21. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother 1999;33:1026-1031.